Discover
CNSP
CNS Pharmaceuticals, Inc.
4.68
2 x 3.50
2 x 5.79
bid
ask
-
0.22
4.49%
2 @ 04:14 AM
4.46 -0.22 (4.70%)
| Ytd | -10.86% | |
| 1y | -54.16% |
4.53
day range
4.93
1.90
52 week range
12.36
| Open | 4.68 | Prev Close | 4.90 | Low | 4.53 | High | 4.93 | Mkt Cap | 6.84M |
| Vol | 13.99K | Avg Vol | 1.43M | EPS | -24.12 | P/E | N/A | Forward P/E | -0.28 |
| Beta | 1.05 | Short Ratio | 0.04 | Inst. Own | 0.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 4.68 | 200-d Avg | 5.51 | 1yr Est | 0.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.25 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | -6.72 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -20.5 | N/A | N/A |
| 2024-04-01 | 2023-12 | 0 | -47.5 | N/A | N/A |
| 2023-11-14 | 2023-09 | 0 | -54 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -52 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-31 | CLIMACO JOHN M | Chief Executive Officer | 215.68K | Purchase |
| 2024-01-31 | DOWNS CHRISTOPHER | Chief Financial Officer | 103.44K | Purchase |
| 2024-01-31 | EVANS CARL ANTHONY | Director | 33.46K | Purchase |
| 2024-01-31 | GUMULKA JERZY | Director | 43.01K | Purchase |
| 2023-03-27 | PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Geode Capital Management, LLC | 203.18K | 22.15K | 0.35% |
| 2024-09-29 | UBS Group AG | 181.87K | 19.82K | 0.32% |
| 2024-09-29 | Virtu Financial LLC | 122.88K | 13.39K | 0.21% |
| 2024-09-29 | Goldman Sachs Group Inc | 28.20K | 3.07K | 0.05% |
| 2024-09-29 | Jane Street Group, LLC | 23.16K | 2.52K | 0.04% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 16.30K | 1.78K | 0.03% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 162.18K | 17.68K | 0.28% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 37.94K | 4.14K | 0.07% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.17K | 127.00 | 0.00% |
| 2024-09-29 | Blackstone Alternative Multi-Strategy Fund | 8.00 | 0.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2025-07-22 |
| 1 : 50 | 2025-02-21 |
| 1 : 50 | 2024-06-05 |
| 1 : 30 | 2022-11-29 |